Table 2.

Summary of studies on COVID-19 in cancer patients

Study	Study design	Sample, n	Cancer type	Key findings
Liang et al. [31]	Retrospective review of a prospective cohort in China (data cut-off January 31, 2020)	18	5 lung cancer; 4 colorectal cancer; 3 breast cancer; 2 bladder cancer; 1 adrenal neoplasms; 1 renal cancer; 1 lymphoma; 1 thyroid cancer	Cancer patients had higher risk of severe events (7/18; 39%) than non-cancer patients (124/1,572; 8%) Cancer patients had shorter median time to deterioration than non-cancer patients (13 vs. 43 days)
Wu and McGoogan [3]	Data summary from Chinese center of disease control (as of February 11, 2020)	107	N/A	Numerically higher fatality rate (5.6%) in cancer patients as compared to the fatality rate of 2.3% in general COVID-19 patients
Zhang et al. [33]	Retrospective cohort of cancer patients with COVID-19 infection from 3 hospitals in Wuhan (January 13 to February 26, 2020)	28	7 lung cancer; 4 esophageal cancer; 3 breast cancer; 2 HCC; 2 laryngeal cancer; 2 prostate cancer; 1 cervical cancer; 1 gastric cancer; 1 rectal cancer; 1 nasopharyngeal cancer; 1 endometrial cancer; 1 ovarian cancer; 1 testicular cancer	Adverse outcomes with mortality rate (8/28; 28.6%); ICU admission rate (6/28; 21.4%); mechanical ventilation rate (10/28; 35.7%) Recent use of antitumor treatment ≤14 days was a risk factor for severe events of COVID-19
Yu et al. [5]	Retrospective cohort of cancer patients in a tertiary hospital in Wuhan (December 30, 2019, to February 17, 2020)	12	7 lung cancer; 2 colorectal cancer; 2 pancreatic cancer; 1 breast cancer; 2 urothelial cancers	Infection rate of COVID-19 appeared to be higher in cancer patients (0.79%) as compared to the incidence of COVID-19 in Wuhan (0.37%) In patients with lung cancer, age ≥60 years had a higher incidence of COVID-19 than age ≤60 years (4.3 vs. 1.8%)
Iavarone et al. [34]	Retrospective comparison of the treatment modality of HCC between February 24 and March 20, 2020 vs. February 25 and March 22, 2019	42	All HCC	A delay of ≥2 months was observed in 11 (26%) patients Thermal ablations were performed in 3 patients instead of preplanned surgical resection
Garassino (TERAVOLT) [55]	Registry (as of April 12, 2020)	200	All lung cancers	Adverse outcomes with high mortality (34.6%) and ARDS rates (26.8%)

ARDS, acute respiratory distress syndrome; HCC, hepatocellular carcinoma; N/A, not available.